Avidity Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Avidity biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Avidity Biosciences Today - Breaking & Trending Today

Arthur A. Levin Sells 40,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 40,000 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.07, for a total transaction of $1,402,800.00. Following the completion of the transaction, the director now directly owns […] ....

Los Angeles , United States , Arthura Levin , Los Angeles Capital Management , Proshare Advisors , Cantor Fitzgerald , Avidity Biosciences Company Profile , Avidity Biosciences Inc , Alps Advisors Inc , Board Of Administration Florida Retirement System , Needham Company , Hennion Walsh Asset Management Inc , Securities Exchange Commission , Avidity Biosciences , Get Free Report , Director Arthur , Exchange Commission , Chardan Capital , Florida Retirement System , Angeles Capital Management , Walsh Asset Management , Share Advisors , Alps Advisors , Avidity Biosciences Daily ,

Avidity shares rise on FSHD data, plans for registrational study

Shares of Avidity Biosciences Inc. hit a 52-week high on reports of promising data from the first efficacy cohort of its phase I/II Fortitude study testing delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD), including impressive biomarker results that could indicate a path for potential accelerated approval. ....

Avidity Biosciences Inc , Avidity Biosciences ,

Avidity Up 33% on Rare Muscle Disease Study Results

Avidity Up 33% on Rare Muscle Disease Study Results
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Avidity Biosciences ,

Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics (NASDAQ:ARQT), Heron Therapeutics (NASDAQ:HRTX)

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles. ....

United States , Marinus Pharmaceuticals , Arcutis Biotherapeutic , Heron Therapeutics , Arcutis Biotherapeutics , Earnings Of Marinus Pharmaceuticals , Society International Research Congress , Avidity Biosciences Inc , Avidity Bioscience , International Research Congress , Avidity Biosciences , Zacks Rank , Marinus Pharmaceutical , Heron Therapeutic ,